These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8066398)

  • 1. [Medical treatment of prostate cancer].
    Lobel B; Cipolla B; Labrador J
    Rev Prat; 1994 Mar; 44(5):611-5. PubMed ID: 8066398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced prostate cancer: what's new in hormonal manipulation?
    Brewster SF; Gillatt DA
    Br J Hosp Med; 1993 May 19-Jun 1; 49(10):710-1, 714-5. PubMed ID: 7686805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economical data and advanced prostate carcinoma: do we need new guidelines for decision making?
    Rohde V; Wellmann A; Fogt F; Weidner W; Katalinic A
    Oncol Rep; 2002; 9(6):1185-8. PubMed ID: 12375016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Conservative therapy of prostate cancer].
    Leitenberger A; Altwein JE
    Fortschr Med; 1991 Sep; 109(28):563-7. PubMed ID: 1721888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The potential hormonal therapy of prostatic carcinoma].
    Studer UE; Altwein J; Bartsch G
    Urologe A; 1991 Sep; 30(5):310-6. PubMed ID: 1949440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone therapy for locally advanced prostate cancer.
    Fowler JE; Bigler SA; White PC; Duncan WL
    J Urol; 2002 Aug; 168(2):546-9. PubMed ID: 12131306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormonal therapy (medical orchiectomy) in prostatic carcinoma].
    Studer UE; Münch D
    Schweiz Med Wochenschr; 1990 Jun; 120(24):881-7. PubMed ID: 2193381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
    Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM
    J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
    Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
    BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maximal androgen blockade versus total androgen suppression.
    Dumez H; Van Poppel H; Baert L; Paridaens R
    Acta Urol Belg; 1997 Mar; 65(1):49-54. PubMed ID: 9175283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostatic cancer in the male under age 60].
    Maier U; Nuehold N
    Wien Klin Wochenschr; 1988 Sep; 100(17):577-9. PubMed ID: 3188531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal treatment in prostate cancer.
    Zbranca E; Preda C
    Endocrinologie; 1991; 29(1-2):91-7. PubMed ID: 1803495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J
    Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
    Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
    J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.